Alberto Chiappori

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer”.

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2742

N/A

1.8DataRank · unranked

70 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa +13 more

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer

Nature Communications(2021)10.1038/s41467-021-24164-y

N/A

0DataRank · unranked

164 citations

Moises J. Velez, Alberto Chiappori, Yoo Sun Kim, Jun S. Wei, Sivasish Sindiri +13 more

A gene expression platform to predict benefit from adjuvant external beam radiation in resected non-small cell lung cancer

medRxiv(2021)10.1101/2021.01.31.21250879

N/A

0DataRank · unranked

2 citations

Ben Creelan, Jeffrey Peacock, Eric A. Mellon, Youngchul Kim, G. Daniel Grass +7 more

Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy

Cancers(2023)10.3390/cancers15092521

N/A

0DataRank · unranked

4 citations

Andreas Saltos, Trevor Rose, Zachary Thompson, Ram Thapa, Alberto Chiappori +2 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020

N/A

0DataRank · unranked

0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more

Data from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

(2023)10.1158/1078-0432.c.6531020.v1

N/A

0DataRank · unranked

0 citations

Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, R. K. Thapa +13 more